Li, Xiaomeng, Li, Xiaowei, Zhang, Kaige, Guan, Yanglong, Fan, Meiyang, Wu, Qian, Li, Yue, Holmdahl, Rikard, Lu, Shemin, Zhu, Wenhua, Wang, Xiaoqin, and Meng, Liesu
We report a novel biomarker, the antibodies to Endophilin A2 (EA2), for early detection of breast cancer, which represents an improvement over existing serological tumor marker. Combined with the existing serum tumor markers, the positive rate of early breast cancer patients could be significantly improved. With regard to clinical application, EA2 antibody appears to be a diagnostically sensitive biomarker and can therefore serve as a more convenient and accurate auxiliary tool. [Display omitted] • We report a novel biomarker, the antibodies to Endophilin A2, for early detection of breast cancer which represents an improvement over existing serological tumor marker. • Serum Endophilin A2 antibody level has suggestive effect on a variety of cancers, including breast cancer, liver cancer, stomach cancer, and colon cancer. Among them, the diagnosis effect of breast cancer is the best, especially for early breast cancer patients. • We have established a mature detection method, which is convenient, reproducible and more suitable for clinical use. • The combined detection of multiple tumor markers significantly improves the detection rate of early breast cancer patients. Due to the lack of early symptoms, breast cancer is frequently overlooked, leading to distant metastases and multi-organ lesions that directly threaten patients' lives. We have identified a novel tumor marker, antibodies to endophilin A2 (EA2), to improve early diagnosis of breast cancer. Antibody levels of EA2 were analyzed in sera of patients with cancers of different origins and stages by indirect enzyme-linked immunosorbent assay (ELISA). Diagnostic accuracy and reference range were determined by the area under the receiver operating curve and distribution curve. The levels of EA2 antigen in sera were determined by sandwich ELISA. The levels of antibodies against EA2 were higher in sera of patients with breast cancer (P < 0.0001), liver cancer (P = 0.0005), gastric cancer (P = 0.0026), and colon cancer (P = 0.0349) than those in healthy controls, but not in patients with rectal cancer (P = 0.1151), leukemia (P = 0.7508), or lung cancer (P = 0.2247). The highest diagnostic value was for breast cancer, particularly in early cases (AUC = 0.8014) and those with distant metastases (AUC = 0.7885). The titers of EA2 antibodies in sera were correlated with levels of EA2 antigen in breast cancer patients. Antibodies to EA2 are novel blood biomarkers for early diagnosis of breast cancer that warrants further study in larger-scale cohort studies. [ABSTRACT FROM AUTHOR]